Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, ...

Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET. Company Participants. Vincent Anzalone - Vice President of Investor Relatio ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31 ...

The Pasadena, Calif., biotechnology company, which uses RNA interference to develop treatments, said Monday it recorded a profit of $370.4 million, or $2.75 a share, during the fiscal second quarter, ...

ARROWHEAD PHARMACEUTICALS ($ARWR) posted quarterly earnings results on Monday, May 12th. The company reported earnings of $2.75 per share, beating estimates of -$0.20 ...

Arrowhead Pharmaceuticals Inc. (ARWR), with a market capitalization of $1.77 billion, posted unexpectedly strong financial results for Q2 FY2025, reporting a net income of $370.4 million, or $2.75 per ...